CLN-049 now has FDA fast track designation for hard-to-treat AML
The U.S. Food and Drug Administration (FDA) has granted fast track designation to the experimental medicine CLN-049, which is being developed as a potential treatment…
Blood cancer
Blood cancer overview
Blood cancer is a broad term encompassing diseases in which blood cells grow too much or develop abnormally. Typically, blood cancers are classified into three main categories – leukemia, lymphoma, and myeloma – but they can be further divided into dozens of specific types, each with unique features.
Read moreTreatments for blood cancers
A wide range of therapies are available for treating blood cancer, from chemotherapy and targeted therapy to radiation, stem cell transplant, and surgery. When devising a suitable treatment plan for blood cancer, healthcare providers take into account various factors, such as age, overall health, the specific type of blood cancer, and potential treatment side effects.
Read moreLatest news
AML drug Komzifti added to national treatment guidelines
Komzifti (ziftomenib), a once-daily oral therapy approved for certain people with acute myeloid leukemia (AML), is now included in the National Comprehensive Cancer Network (NCCN)…
New ‘powerful’ lab test will help researchers explore blood cancer
Mission Bio has debuted a new laboratory test that enables researchers to simultaneously detect alterations in the genetic code and changes in genetic activity…
FDA approves ziftomenib to treat some relapsed leukemia patients
The U.S. Food and Drug Administration (FDA) has approved ziftomenib to treat adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1…
CAR T-cell therapy candidate yields lasting response in tough lymphoma
One-time treatment with vispa-cel (CB-010), Caribou Biosciences’ off-the-shelf CAR T-cell therapy candidate, resulted in durable responses in people with hard-to-treat large B-cell lymphoma (LBCL).
Cero seeking more safety, dosing data on T-cell therapy for AML
A third dose of CER-1236, Cero Therapeutics’ T-cell therapy candidate for acute myeloid leukemia (AML), was administered to an AML patient taking part in…
